Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.
about
Modified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study.Pharmacological treatment for generalized anxiety disorder in adults: an update.Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety DisorderQuetiapine: novel uses in the treatment of depressive and anxiety disorders.Treatment strategies for dosing the second generation antipsychotics.Benzodiazepines revisited--will we ever learn?Pharmacological treatment of generalized anxiety disorder.Co-occurrence of anxiety and bipolar disorders: clinical and therapeutic overview.Withdrawing Benzodiazepines in Patients With Anxiety Disorders.The effect of quetiapine (Seroquel™) on conditioned place preference and elevated plus maze tests in rats when administered alone and in combination with (+)-amphetamine.A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.
P2860
Q33695930-505E8B48-5A1F-495D-8F5B-10EF33F99D81Q34484276-E6F0B5BB-042F-4A7D-B5B3-FE82B7B59ECBQ36062003-AF51E119-7785-4FC3-9319-44525B147980Q36208776-76EB9A9B-5484-46F3-87D4-FF4C90B72152Q36275903-8770824D-3C5F-4DBC-8784-54516D959C7DQ37299931-E982C3B0-CF4B-4730-8F36-64A53033A6EEQ37783300-73285B7C-2190-4BDC-824F-A222C631C08DQ37852818-14F4A725-C26A-408D-8118-D59290F83549Q37895716-8B582806-F7D9-4F5D-A6D0-BC690EE8565EQ37939221-7948D904-EB0A-4EB8-9D48-995DCCB24DA9Q38194541-35094901-96E5-41B2-A1F3-627435489D58Q38687615-0AEF8F7E-FDA7-4E91-83CD-A291AA8357EEQ39197723-1619E749-5C64-40F0-BE69-4C3E6AEDC187Q47878230-311D92E0-9B0B-43F3-9B3C-B894726C8A4A
P2860
Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Atypical antipsychotics in pri ...... comorbid with mood disorders.
@ast
Atypical antipsychotics in pri ...... comorbid with mood disorders.
@en
type
label
Atypical antipsychotics in pri ...... comorbid with mood disorders.
@ast
Atypical antipsychotics in pri ...... comorbid with mood disorders.
@en
prefLabel
Atypical antipsychotics in pri ...... comorbid with mood disorders.
@ast
Atypical antipsychotics in pri ...... comorbid with mood disorders.
@en
P2860
P356
P1476
Atypical antipsychotics in pri ...... r comorbid with mood disorders
@en
P2093
Joseph R Calabrese
Keming Gao
P2860
P304
P356
10.1586/ERN.09.37
P577
2009-08-01T00:00:00Z